Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab

Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab

(1) Background: Ipilimumab plus nivolumab (combo-ICI) improves overall survival (OS) in patients with advanced renal cell carcinoma (RCC) or melanoma. The impact of bone metastases (BM) on survival outcomes of combo-ICI-treated patients is unknown. (2) Methods: This single-center retrospective obser...

Full description

Bibliographic Details
Main Authors: Félix Pham, Samy Belkaid, Denis Maillet, Cyrille B. Confavreux, Stéphane Dalle, Julien Péron
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Biomedicines
Subjects:
ipilimumab
nivolumab
renal cell carcinoma
melanoma
bone metastases
neutrophils-to-lymphocytes ratio
Online Access:https://www.mdpi.com/2227-9059/10/11/2758

Internet

https://www.mdpi.com/2227-9059/10/11/2758

Similar Items